Engineered immune cells target tough leukemia in early trial
NCT ID NCT03244306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new treatment for children and young adults with a type of leukemia that came back or did not respond to standard therapy. The approach uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein called CD22. The main goals were to see if the treatment was safe and if the modified cells could be made successfully for each patient.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- A guided path back to work after blood cancer: a trial tests the impact
- Can a new tracer light up cancer growth?
- Can a different immune drug cut viral infections after stem cell transplants?
- Can simple seated exercises boost strength and Well-Being during leukemia treatment?
- Can a Child's own words improve cancer care?